Venkatadri Bobba has over 36 years of corporate leadership experience in the pharma and life sciences industries
Cancer Genetics, provider of DNA-based cancer diagnostics, has announced the addition of Venkatadri Bobba to Cancer Genetics India’s Board of Directors.
“Bobba has a tremendous track record of leadership in the life sciences. His experiences and insights will bring significant value to CG India’s board of directors,” said Panna Sharma, CEO and President of Cancer Genetics.
Bobba has over 36 years of corporate leadership experience in the pharma and life sciences industries, informs a company release. Bobba, who is currently a General Partner with Ventureast, has held executive leadership positions at a number of life sciences companies in the US, EU, and Asia. Prior to joining Ventureast, Bobba served as Senior VP of Operations at Aradigm Corporation and from 2001-2003 was Executive Vice President at Diosynth, a division of Akzo Nobel. From 1995 to 2000, Bobba served as President and CEO at Molecular Biosystems. Previous to that, Bobba was Executive Vice President of Centocor Inc (now Jansen Biotech, a division of Johnson & Johnson) and held several executive positions, including President, at Warner-Lambert, Indonesia. He also previously served as VP of Manufacturing at Parke-Davis, US (now part of Pfizer).
It is an exciting time to be part of such a high-growth market like India. I look forward to the growth and much needed innovation that CG India will bring to Indian cancer patients and hospitals at an affordable price,” said Bobba. “CG India has established itself as a leader in the oncology diagnostics market with a firm commitment to innovation. I look forward to helping the company offer novel cancer diagnostic tests to all patients who needs them to improve their clinical outcomes.”
Bobba is an active board member of three US-based companies, including Diabetomics, Melior Pharma, and Sparsha. Bobba also sits on the board of several Indian-based companies, including Portea, Richcore, and Sparsha Pharma, an Indian subsidiary of Napo Pharmaceuticals. Additionally, he serves on the advisory board for the SOHO Group, the largest pharma company in Indonesia, and for Cumberland Pharmaceuticals.
A pharmacist by training, Bobba graduated with gold medal honors from Andhra University and holds an MBA from Farleigh Dickinson University, New Jersey.
Cancer Genetics, provider of DNA-based cancer diagnostics, has announced the addition of Venkatadri Bobba to Cancer Genetics India’s Board of Directors.
“Bobba has a tremendous track record of leadership in the life sciences. His experiences and insights will bring significant value to CG India’s board of directors,” said Panna Sharma, CEO and President of Cancer Genetics.
Bobba has over 36 years of corporate leadership experience in the pharma and life sciences industries, informs a company release. Bobba, who is currently a General Partner with Ventureast, has held executive leadership positions at a number of life sciences companies in the US, EU, and Asia. Prior to joining Ventureast, Bobba served as Senior VP of Operations at Aradigm Corporation and from 2001-2003 was Executive Vice President at Diosynth, a division of Akzo Nobel. From 1995 to 2000, Bobba served as President and CEO at Molecular Biosystems. Previous to that, Bobba was Executive Vice President of Centocor Inc (now Jansen Biotech, a division of Johnson & Johnson) and held several executive positions, including President, at Warner-Lambert, Indonesia. He also previously served as VP of Manufacturing at Parke-Davis, US (now part of Pfizer).
It is an exciting time to be part of such a high-growth market like India. I look forward to the growth and much needed innovation that CG India will bring to Indian cancer patients and hospitals at an affordable price,” said Bobba. “CG India has established itself as a leader in the oncology diagnostics market with a firm commitment to innovation. I look forward to helping the company offer novel cancer diagnostic tests to all patients who needs them to improve their clinical outcomes.”
Bobba is an active board member of three US-based companies, including Diabetomics, Melior Pharma, and Sparsha. Bobba also sits on the board of several Indian-based companies, including Portea, Richcore, and Sparsha Pharma, an Indian subsidiary of Napo Pharmaceuticals. Additionally, he serves on the advisory board for the SOHO Group, the largest pharma company in Indonesia, and for Cumberland Pharmaceuticals.
A pharmacist by training, Bobba graduated with gold medal honors from Andhra University and holds an MBA from Farleigh Dickinson University, New Jersey.
No comments:
Post a Comment